Biomedical subjects

T Storaas

Publications and source records attributed to T Storaas.

4 recordsLinked to original sources

PubMed2004

A new pulse sequence to visualize slow flow.

The purpose of this paper is to present a new pulse sequence for visualizing slow flow. The new sequence consists of an initial Stejskal-Tanner flow sensitization part followed by a DEFT pulse and a spoiler gradient. A single-shot TSE readout train is then applied to sample the NMR signal. The sequence was initially tested using a simple flow phantom. To verify potential clinical use, both flow-sensitive MRCP and cerebrospinal fluid (CSF) images were produced. The phantom study proved the sequence sensitivity to flow in the range 0-1 cm/s. bVE-factors 1.5, 3, 6 and 12 were chosen. Within this flow velocity range, the signal dropped as predicted theoretically. This indicates that the method can be used to quantify flow. All anatomical features seen in a standard MRCP sequence were identified and the methods sensitivity to CSF flow was demonstrated by sagital images of the head. A new pulse sequence sensitive to slow flow has been developed.

Cerebral Ventricles↗

PubMed2004

Dynamic first pass 3D EPI of the prostate: accuracy in tumor location.

PURPOSE: To evaluate the potential of dynamic contrast enhanced (DCE) 3D EPI in the location of prostate cancer. MATERIAL AND METHODS: A DCE 3D EPI scan was included in the magnetic resonance imaging protocol for prostate examination. Twenty-eight patients who subsequently underwent radical prostatectomy were included in the study. T2-weighted (T2W) Turbo Spin Echo (TSE) images were initially evaluated by two radiologists. Parametric images reflecting contrast enhancement were added and new evaluations performed. The results were compared with histology from resected specimens. Accuracies and interobserver agreements were calculated. RESULTS: Interobserver agreement was Kw =49+/-3% for the T2W technique and Kw=30+/-3% for the combined techniques. No statistically significant advantages were found for location of tumor in the prostate or in the seminal vesicles by adding the DCE information. CONCLUSION: DCE 3D EPI did not improve tumor location compared with that of T2W TSE images. Further investigation is needed on how best to exploit the DCE technique.

Aged↗

PubMed2002

Bowel MR imaging with oral Gastrografin: an experimental study with healthy volunteers.

Our objective was to evaluate Gastrografin for MR bowel imaging. Twenty-three healthy volunteers in two randomised groups received 300 or 400 ml 50% Gastrografin, drunk continuously during 2 and 3 h, respectively. Images were applied during breath-hold in three orthogonal orientations. The balanced fast-field echo (BFFE) and balanced turbo field-echo (BTFE) sequences, with acquisition times from 13 to 25 s, were used before gadolinium (Gd) DTPA implying 1- to 2-mm-thick slices locally or 6-mm-thick slices through the entire gastrointestinal tract. The Gd-enhanced images were performed using a 3D T1-weighted FFE sequence with water selective excitation (Proset). Image quality, including bowel distention, homogeneity of opacification and wall conspicuity, were evaluated by two experienced reviewers, and the adverse reactions were recorded. Very good or excellent distention, homogeneity and wall conspicuity were achieved in the central segments from the ileum to the left colon flexure in 83-96% of cases, due to the adequate contrast media supply in these regions. Distention, homogeneity and delineation were good in the central segments of the remaining bowels. Diarrhoea was a major problem affecting all participants, followed by nausea. Provided that there is modern fast sequential technology, excellent MR imaging of the bowel can be achieved by the oral administration 50% diluted Gastrografin. Further studies are needed to refine the technique and optimise the quantity and concentration of Gastrografin in order to avoid or reduce adverse reactions.

Administration, Oral↗

PubMed2000

Effects of benzalkonium chloride on innate immunity physiology of the human nasal mucosa in vivo.

OBJECTIVE: Benzalkonium chloride (BC) is a preservative commonly used in nasal decongestant sprays. It has been suggested that BC may be harmful to the nasal mucosa. The present study, involving healthy volunteers, examines effects of BC on nasal mucosal end-organ functions. METHODS: Isotonic saline and BC (0.1 mg/mL) were administered acutely to the nasal mucosa using a nasal pool device. Nasal symptoms were determined. Nasal lavage fluid levels of alpha2-macroglobulin and fucose were measured as indices of plasma exudation and glandular secretion, respectively. In addition, BC (0.1 mg/mL) was given as single actuations of 100 microL per nasal cavity three times daily for 10 days. The ability of histamine (0.4 mg/mL) to evoke nasal symptoms and plasma exudation responses was determined before and after the repeated BC administration series. RESULTS: BC produced immediate nasal smart or pain (P < .05), but tolerance to this response developed by repeated administrations. BC increased nasal mucosal output of fucose (P < .05), whereas nasal lavage fluid levels of alpha2-macroglobulin were unaffected. Histamine produced significant symptoms and mucosal exudation of alpha2-macroglobulin (P values < .01), equally before and after the 10 days of BC exposure. CONCLUSIONS: BC in dosages commonly used as preservative in nasal decongestant sprays produced short-term glandular secretion and nasal smart or pain. However, 10 days' frequent exposure to BC was not associated with untoward symptomatic effects, nor was a sensitive mucosal variable such as histamine-induced exudative responsiveness affected by this repeated exposure 1 BC.

Administration, Topical↗